Mirabegron (ER) 25 mg/50 mg and Solifenacin 5 mg/5 mg Tablet
Product Description
Windlas Biotech Limited
-
IN -
2022On CPHI since
-
3Certificates
-
500 - 999Employees
Company types
Primary activities
Categories
Specifications
Windlas Biotech Limited
-
IN
-
2022On CPHI since
-
3Certificates
-
500 - 999Employees
Company types
Primary activities
More Products from Windlas Biotech Limited (3)
-
Product Dapagliflozin 5 mg/5 mg, Sitagliptin 50 mg/50 mg, Metformin (IR) 500 mg/1000 mg Tablet
DCGI approval with Windlas -
Product Linagliptin 5mg + Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg Tablet
Fixed dose combination of Dapagliflozin and Linagliptin tablet can be used as a superior treatment alternative in patients with type 2 diabetes mellitus inadequately controlled on Metformin. Despite of their distinct mechanism of actions, these drugs act collaboratively by decreasing the glycaemic index... -
Product Rosuvastatin 40 mg and Ezetimibe 10 mg FDC Tablets
Fixed dose combination of Rosuvastatin and Ezetimibe can be a superior alternative for the treatment of patients with primary hypercholesterolemia. The lipid lowering efficacy of combination therapy with Rosuvastatin and Ezetimibe is greater than that of their monotherapy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance